RCSD1 RCSD1::ABL1

CI-VAR-00005083Explore in graph →CIViC 2891

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Childhood B-cell Acute Lymphoblastic Leukemia1unmapped disease
RCSD1 RCSD1::ABL1	Imatinib	Predictive	C	Supports Sensitivity Response	3	rejected	EID7782 In the case report, it has been stated that the patient with known B-cell precursor ALL was induced to remission by imatinib, a tyrosine kinase inhibitor that affects the following eight ABL1 fusion p… (full text at CIViC) PMID 27125982 · Perwein et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.